The clinical relevance of these findings is increased by observations, supported by NSCLC clinical trials, suggesting that EGFR-driven ESCCs are unlikely to respond well, or durably, to immune checkpoint inhibitors used in adjuvant and palliative care settings in ESCC, and so require alternate treatment strategies. Here, EGFR is linked to esophageal squamous cell carcinoma.